Shattuck Labs Inc Ordinary Shares STTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
-
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
-
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
-
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Trading Information
- Previous Close Price
- $5.60
- Day Range
- $5.36–5.60
- 52-Week Range
- $1.72–8.33
- Bid/Ask
- $4.73 / $5.49
- Shares Outstanding
- 100.36M
- Market Cap
- $550.99M
- Volume/Avg
- 700,502 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 576.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- https://www.shattucklabs.com
Valuation
|
Metric
|
STTK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.62 |
Price/Sales | 576.08 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
STTK
|
|---|---|
Quick Ratio | 26.94 |
Current Ratio | 27.59 |
Interest Coverage | — |
Quick Ratio
STTK
Profitability
|
Metric
|
STTK
|
|---|---|
Return on Assets (Normalized) | −38.06% |
Return on Equity (Normalized) | −40.80% |
Return on Invested Capital (Normalized) | −39.80% |
Return on Assets
STTK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|FF@gD? | LOCK|Hps?h | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|bc?v@h | LOCK|$C&> | $83B | |||
| Moderna Inc
MRNA
| LOCK|?x?J?^x | LOCK|cf | $80B | |||
| argenx SE ADR
ARGX
| LOCK|^DFl>^ | LOCK|%j^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FS%?!L | LOCK|>w | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|g#?x$X | LOCK|q@t?h | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|h#NccskV | LOCK|xjKY | $28B | |||
| Incyte Corp
INCY
| LOCK|xvGB#Q^ | LOCK|%G% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|m$G>$M | LOCK|@K | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%$hfPW! | LOCK|<PV | $14B |
United States